Clinical Trial Update: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS [Phase 1]

View source ↗

Summary

Phase 1, open-label study of intravenous GSK3745417 in relapsed/refractory myeloid malignancies (AML and high-risk myelodysplastic syndrome). The trial was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• GSK3745417

Snippet

Sponsor: GlaxoSmithKline | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: TERMINATED | Results posted: 2025-03-25